Bureau Veritas Defines New Direction with Food Business Sale
Bureau Veritas, a leading name in Testing, Inspection, and Certification services, has made a strategic decision to refocus its portfolio. The company announced an agreement to sell its Food testing business to Mérieux NutriSciences, which is set to enhance its operational capabilities and align with Bureau Veritas’ LEAP | 28 strategy.
Significance of the Asset Transfer
Through this transaction, Bureau Veritas aims to streamline its operations, allowing for greater focus on markets where it aspires to lead. The Food testing business, generating EUR 133 million in revenue in 2023, represents a significant asset and its sale will take place for an enterprise value of EUR 360 million, expected to bring in net proceeds of about EUR 290 million.
Growth through Strategic Divestment
By divesting this segment, Bureau Veritas plans to apply the proceeds toward enhancing its merger and acquisition strategies, necessary to meet its ambitious targets set for 2028. This move is anticipated to improve the Group's adjusted operating margins while maintaining a neutral impact on adjusted net profit heading into 2025.
CEO Insights on the Agreement
Hinda Gharbi, the CEO of Bureau Veritas, highlights the significance of this deal: “This divestment demonstrates our active portfolio management, in line with the Focused Portfolio pillar of our strategic plan. The transaction strengthens our balance sheet and gives us greater leeway to implement our ambitious acquisition plan.”
About Mérieux NutriSciences
Mérieux NutriSciences is recognized as a critical player in the food testing sector, and the acquisition of Bureau Veritas’ Food testing business marks a pivotal moment for the company. Nicolas Cartier, CEO of Mérieux NutriSciences, stated, “This will significantly expand our geographic coverage, consolidating a strong presence on every continent, which enhances our ability to serve customers effectively.”
The Future Ahead
Both organizations view this partnership as a way to contribute to safer and more sustainable food systems globally. Upon closing, Mérieux NutriSciences will integrate approximately 1,900 professionals transitioning from Bureau Veritas, enriching its workforce and capabilities.
Anticipated Closing Timeline
The transaction is expected to conclude by the end of the fourth quarter of 2024, pending the fulfillment of customary closing conditions, including requisite regulatory approvals across various regions.
About Bureau Veritas
Bureau Veritas has stood as a hallmark of quality in inspection, certification, and testing services since its establishment in 1828. With a passionate commitment to fostering trust, the organization works tirelessly to help businesses navigate their evolving challenges.
With approximately 83,000 employees around the globe, Bureau Veritas is renowned for its innovative services that help clients achieve excellence in quality, health and safety, environmental protection, and sustainability. The company is actively traded on Euronext Paris and is part of several significant indices, including the CAC 40 ESG.
Frequently Asked Questions
What is the focus of Bureau Veritas' LEAP | 28 strategy?
The LEAP | 28 strategy focuses on concentrating the company's portfolio on key markets where it aims to establish top leadership and performance by the year 2028.
How will the sale of the Food testing business benefit Bureau Veritas?
This sale will provide Bureau Veritas with significant net proceeds, estimated at EUR 290 million, which will be used to support future mergers and acquisitions, further strengthening its market position.
Who is acquiring the Food testing business?
The Food testing business is being acquired by Mérieux NutriSciences, a well-known leader in the food safety and testing sector.
What types of services were provided by the Food testing business?
Services offered by this business included microbiology testing, chemical analysis, and a variety of other laboratory activities within the food sector.
When is the transaction expected to close?
The transaction is anticipated to close by the end of the fourth quarter of 2024, subject to customary closing conditions and regulatory clearances.
